Proteins

Product Data Sheet



YB-0158

Cat. No.: HY-136541 CAS No.: 1144043-83-3 Molecular Formula: $C_{32}H_{32}N_7Na_2O_7P$

Molecular Weight: 703.59

Target: Wnt; Apoptosis

Pathway: Stem Cell/Wnt; Apoptosis

Storage: 4°C, sealed storage, away from moisture

* In solvent: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

SOLVENT & SOLUBILITY

In Vitro

DMSO: 100 mg/mL (142.13 mM; Need ultrasonic)

H₂O: < 0.1 mg/mL (ultrasonic;adjust pH to 1 with 1M HCl) (insoluble)

Preparing Stock Solutions	Solvent Mass Concentration	1 mg	5 mg	10 mg
	1 mM	1.4213 mL	7.1064 mL	14.2128 mL
	5 mM	0.2843 mL	1.4213 mL	2.8426 mL
	10 mM	0.1421 mL	0.7106 mL	1.4213 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

- 1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.5 mg/mL (3.55 mM); Clear solution
- 2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.5 mg/mL (3.55 mM); Clear solution
- 3. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.5 mg/mL (3.55 mM); Clear solution

BIOLOGICAL ACTIVITY

Description	YB-0158 (Wnt pathway inhibitor 2) is a reverse-turn peptidomimetic and a potent colorectal cancer stem cell (CSC) targeting agent. YB-0158 disrupts Sam68-Src interactions and induces apoptosis in CRC cells. Anti-cancer activities ^[1] .
IC ₅₀ & Target	Wnt signaling $^{[1]}$
In Vitro	YB-0158 (0.2 μ M and 0.5 μ M; 48 hours) significantly increases apoptosis in CRC cells as represented by activated Caspase-3/7 detection assays ^[1] . YB-0158 (0.3 μ M) similarly decreases CBP recruitment at the promoter of Wnt/beta-Catenin target genes LGR5 and MYC in

	HT29 cells, compared with DMSO control ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo	YB-0158 displays an EC ₅₀ (1.64 μ M) in cultured MC38 cells. YB-0158 (100 mg/kg; IP; C57BL/6 mice bearing MC38 cells) shows no significant differences in primary tumor size in vivo treatments versus saline controls ^[2] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

CUSTOMER VALIDATION

- iScience. 10 November 2021.
- STAR Protoc. 18 March 2022, 101218.

See more customer validations on $\underline{www.MedChemExpress.com}$

REFERENCES

[1]. Masibag AN, Bergin CJ, Haebe JR, et al. Pharmacological targeting of Sam68 functions in colorectal cancer stem cells. iScience. 2021;24(12):103442.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

 $\hbox{E-mail: tech@MedChemExpress.com}$

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA